



# EIPICO

## Yes We Care

Company Profile 2023



# Message from the Chairman of the Board of Directors

## Message from the Chairman of the Board of Directors

On behalf of the Board of Directors of EIPICO, I would like to present to you our company profile which I trust you will find as a reliable, useful and valuable source of information. Our motto, "Yes, We Care", reflects our assiduous effort and ongoing striving to assist healthcare systems, whether domestically or internationally, by providing high quality pharmaceutical products at reasonable prices.




EIPICO was the leading pharmaceutical company in Egypt to apply Good Manufacturing Practice (GMP), the system for ensuring that products are consistently produced and controlled according to quality standards.

EIPICO is, currently, one of the leading Egyptian pharmaceutical companies, in terms of production and sales, in the local market. It is the leading company in pharmaceutical exports, capturing a 21% share of the total Egyptian pharmaceutical export market.

Our product portfolio comprises more than 400 products, covering more 24 therapeutic classes, including: antibiotics, antivirals, anaesthetics, as well as, ophthalmic, cardiovascular, gastrointestinal, genitourinary and respiratory drugs and many more. Through generating innovative entrepreneurial ideas, meticulous planning, and with the support of hardworking, enthusiastic, diligent, high-performance teams, working in tandem, and committed to their duties, we shall continue to fulfill our mission of expanding our production of high quality products, to satisfy the needs of the medical community.

EIPICO will continue to improve its efficiency in every aspect and will continuously endeavor for evolution, saving no effort to meet the current and future expectations of the healthcare systems and to contribute to the healthcare development of our country. Finally, I would like to express my deepest thanks to our shareholders and to the medical and pharmaceutical professionals for their trust, our partners and suppliers for their support and our employees for their relentless efforts to maintain our position as a leading pharmaceutical company.

Chief Executive Officer



# Our Vision

EIPICO Strives to be the largest provider of pharmaceuticals in the Middle East, Africa, East Europe, Asia and Latin America. and presenting new horizons of innovative drug industry through the Biosimilars production.



# Our Mission

EIPICO dedicates all the resources and latest technologies to provide the highest quality pharmaceutical products with the most affordable price while focusing on its responsibility in the development of health care services reaching every patient worldwide. Without forgetting the crucial role of EIPICO employees in providing and maintaining EIPICO's premium quality achieving profit to all Shareholders.



## Genuine Care

We genuinely care for patients everywhere. We have been able to build trust in our products and we are committed to exerting all efforts to keep the healthcare professionals' and patients' continuous trust.

## Integrity

We believe that doing our jobs with integrity and conscientiousness is the sole key to great achievements.

## Product Quality

We work on the quality of our products to ensure their efficacy and safety are up to the highest standards. Highest quality besides respect for the environment are among our priorities.

## Teamwork

We build high-performance teams working harmoniously together to achieve assigned missions with the best possible results.

## Fairness

We work on the balance of justice, equity and rights distribution, as we believe that these principles will guarantee that our staff will save no efforts to achieve our business goals.

## Empowerment

EIPICO gives the opportunity and confidence to its staff through authorization and delegation to assume responsibilities and contribute to the overall company's success.

## Innovation

EIPICO has a climate that helps creativity and innovation which eventually leads to the continuous development of our business.

# Our Core

V

A

L

U



## High Performance

Our performance is the practical way to express our commitment to the principles and duties of work. We always aim at improving our performance to reach the highest levels.

## Loyalty

The individual affiliation of EIPICO stems from the company's social contributions to the individual and gives the members of EIPICO pride and belonging to their work in the company.

# CSR


- Effective training programs, whether coordinated internally or externally, are created and implemented for the students of the College of Pharmacy. EIPICO trained about 2,800 students nationwide, 300 students in the company's summer internship, and 2500 students through several lectures in universities, in addition to two delegations from Sudan and Yemen. The training programs are constantly monitored, reviewed, evaluated and updated by our experts.



- In cooperation with Baheya Foundation for early detection and treatment of breast cancer, and our company's keenness to preserve the health of workers, empower women, and spread health awareness for women in our community, the Baheya Foundation held an awareness seminar at the company's headquarters to educate the workers about breast cancer and early detection, and medical consultations were made with the surgical medical staff.



- In cooperation with ElSewedy Academy for Technical Education, the company welcomed 15 students to start a scientific and practical program for a period of 3 years, after which the student obtains a technical diploma in pharmaceutical technology approved by the Egyptian Ministry of Education and Technical Education, a Finnish competency certificate approved by FGES and Specialized English Language Certificate accredited by the University of Cambridge in England.



- Every drop of blood means life! that is why we commit to always running voluntary blood donation campaigns under the auspices of the Ministry of Health. To provide the required blood needed in hospitals to save the lives of Egyptian patients.



- EIPICO provided medical supplies with a wide range of more than 350 pharmaceutical products for the treatment of both acute and chronic diseases to around 35 medical convoys covering most of Egypt in 2022.





# Distinctive Production Capabilities

EIPICO Production facility is the beating heart of the company's business. Based on its capability and high performance, the production capability enable EIPICO to attain its remarkable position in the market not only in Egypt but also in the Middle East and North Africa (MENA) Region.

During the last decade, a great upgrading and modifications took place in order to have the best machines and equipment characterized by high speed, and full automation including robotic systems, in addition to conversion of all production departments to smart building units with total control of Temperature, Humidity and Differential pressure between different rooms.

The production system in EIPICO, depends on Total Quality Control with the application of Zero Defect System.

# EIPICO Production Capacity / Year

EIPICO is the Leading Egyptian Pharmaceutical Company, in Production, by Units. EIPICO is the Major Provider of Antibiotics, Lyophilized products and Spansule Capsules, to the Egyptian market.



# Facilities

**Factory 1** was built in 1980 and renewed using state-of-the-art construction system and materials in compliance with International Society for Pharmaceutical Engineering (ISPE) regulations assuring clean environment for all production rooms to provide maximum protection for both products and personnel. The site contains several departments for manufacturing of many Dosage Forms. It includes: the Largest and Most Advanced Sterile Area in Egypt and in the MENA region, separated areas for Sterile Cephalosporin Antibiotics, Sterile Penicillin Antibiotics and Non Sterile (Oral) Antibiotics to prevent cross-contamination with up to date containment systems. Other activities performed in the site include: warehousing, engineering and other administrative functions.



Sterile Ampoules and Vials Department



Sterile Eye Drops Department



Sterile Cephalosporin Antibiotics Powder Area Department (IMA I)



Sterile Cephalosporin Antibiotics Powder Area Department (Perry II)



Sterile Penicillin Antibiotics Powder Area (IMA II) Department



Sterile Penicillin Antibiotics Powder Area (Perry I) Department

# Facilities

**Factory 2** was launched in 2013 to fulfill the ever-growing demand of both national and international markets. The production facilities have been designed to cope with the latest cGMP and WHO regulations. The site's main production building contains 6 Manufacturing Departments which are: Sterile Hormones and Corticosteroids, Sterile Eye Drops, Tablets, Effervescent granules, Syrup and Suspension and Semi solid Departments.



Sterile Hormones Department



Sterile Eye Drops Department




Tablets Department



Effervescent Granules Department



Syrup and Suspension Department



Semi Solid Department

**" Recently new departments are added, BFS department ( Blow Fill & Seal ) for Single-dose eye drops & Aerosol Department for inhaler "**



Aerosol




BFS



# New Production Lines

- EIPICO Ophthalmics already installed the new "Single Dose Unit" (SDU) eye preparations production line, and some SDU brand's batches have been produced waiting for the Egyptian Drug Authority (EDA) to permit and release, in the context of completion of registration regulations, then, EIPICO Ophthalmics will be supply strongly, locally and internationally, the SDU markets, during the 2nd half of 2023.



By the vision of retaining the first rank in the Egyptian Ophthalmic Market, in terms of units, through capturing extra market share & approaching the first rank, in terms of value, within the next few years

- In order to meet the company's strategic development plan and keep pace with the global market and the ability to compete locally and globally, EIPICO has established a new Aerosol line with the latest technology. Delivery of inhaled drugs is a cornerstone of patient management across a range of respiratory diseases, and more recently, the lungs are used as a gateway for drug delivery into the systemic circulation. The new aerosol line of European origin is capable of manufacturing all types of inhalers serving all pharmacological effects for the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease.



## Facilities

- **EIPICO 3** : In order to meet the company's strategic development plans, to establish itself as the first Biological & Biosimilar manufacturer and to reinforce its leading position in the region thus cope with our Presidential Campaign of Localizing Pharmaceutical Industry to supply Egyptian citizens with locally manufactured, high quality, and affordable medicine. In order decrease the need of Hard Currency used in importing of these products.
- Investments around 200 million dollars.
- 7 Products with different concentrations covering Therapeutic groups related to Cancer, Anemia and Infertility.



- A new state of the art Modular Manufacturing Facility, which is a green-field establishment next to the current site in 10th of Ramadan City, Egypt, will be designated for Biological & Biosimilar products and will be the first of its kind in Egypt and in the MENA Region.
- EIPICO will produce and manufacture a number of biosimilar monoclonal antibody products as well as several small protein products in this new facility. These products will be manufactured starting from the Cell Line all the way through Upstream & Downstream. Process to reach Drug Substance (DS) as well as Drug Product (DP) Production. EIPICO 3 is planned to meet future business opportunities through internal expansion.



# EIPICO, The Leading Egyptian Pharmaceutical Company



in Egyptian pharmaceutical market by units.

in systemic Anti-infectives market by units.

Rank # 1

in Ophthalmics market by units.

in Egyptian exports of pharmaceutical products.



# EIPICO fights Covid-19

EIPICO donated thousands of its pharmaceutical products for the management of covid-19 patients.

## Antivirals



## Vitamins



## Antibiotics



## Antibiotics



## Analgesic & Antipyretic



## Systemic Corticosteroids



## Systemic Corticosteroids



## Cough Preparations



# EIPICO Ophthalmics... ..Save Sight

**Rank # 1\***  
In The  
Ophthalmic Market



The Major Supplier  
of Eye Ointments  
In Egypt



The Only  
Fluoroquinolone  
Eye Ointment  
In Egypt



**Steroid &  
Anti-infective**



**Decongestant  
& Antihistamine**

**Dependable  
Ophthalmic  
Medications**



**Antihistamine  
(Multi-Action)**

**Anti-glaucoma**



**Lubricant &  
Artificial Tears**



# Therapeutic Groups

## CEPHALOSPORINS

- CEFOTAX
- EPICEPHIN
- CEFIDIME
- CEFOZON
- CEPHRADINE

## PENICILLINS

- FLUMOX
- E-MOXCLAV
- NOVACTAM
- E-MOX
- EPICOCILLIN

## ANTI-VIRALS

- COVAPRAVIR
- REMAIST
- EPIFLUVER
- EPIMIRAFLU
- EPISOVIR
- DACLADAZIN

## QUINOLONES

- CIPROCIN
- EPINOR
- EPICOFLOCIN

## MACROLIDES

- EPIZITHRO

## ANTIFUNGALS

- TREFLUCAN
- NYSTATIN

## TETRACYCLINES

- DOXYDOX

## AMINOGLYCOSIDES

- EPIGENT

## CARDIOVASCULAR

- ATOR
- EPIROVASTIN
- LOSAZIDE
- RAMPECARDIN / CO
- CO-VASOTEC
- VASOTEC
- EPILAT/RETARD
- REGCOR

## CARDIOVASCULAR

- CAPOTRIL
- DILTIAZEM
- ATENO/C
- DINITRA
- THROMBO
- PROLOL
- ETHANOLAMINE OLEATE

## NSAID'S

- KEVICE
- CETAL
- EPIFENAC
- EPICOTIL
- VASTAFLAM
- MAFO
- TANTUM

## ALIMENTARY & METABOLISM

- NU-SPASM
- REPAGLINIDE
- GLICLA
- PICOLAX
- COLOSPASMIN
- GASTROMOTIL

## ALIMENTARY & METABOLISM

- LIBRAX
- EPIRAZOLE
- MUCOGEL
- EPICOGEL
- GASTROFAIT

## ANTI-PROTOZOALS, ANTHELMINTICS & ANTI-INFECTIVES

- ALZENTAL
- SECNIDAZOLE
- FURAZOL
- EPIQUANTEL
- KAPECT
- KAPECT COMPOUND
- NIFUROX

## VITAMINS & TONICS

- EPICOZYM
- MINERAVIT
- CEVITIL
- EPINOSINE B FORTE
- FERROFOL
- FERROFOLVIT-Z
- FOLIC ACID
- VITONA PLUS

## DIETARY SUPPLEMENTS

- EPICOFERRIN
- EPICOFERRIN PLUS

# Therapeutic Groups

## EYE & EAR PREPARATIONS

- Caffohist
- NAPHCOZOLE
- BENOX
- CIPROCIN
- DEXATOBIN
- DEXATROL
- EPICROM
- EPIDEXONE

## EYE & EAR PREPARATIONS

- EPIFENAC
- EPIPHENICOL
- EPISOPT
- EPITAXOL
- NEO-MYXIDIN
- NEO-POL
- NORMO-TEARS
- NOSTAMINE

## EYE & EAR PREPARATIONS

- OLOHISTINE
- OXY-POL
- TIMOLOL
- TOBRIN
- XALATREX
- XALATREX PLUS

## HORMONES

- EPIFASI
- EPIGONAL
- EPOFORM
- PROGESING

## SYSTEMIC CORTICOSTEROIDS

- EPICOPRED
- EPIDRON
- DEXAMETHASONE
- EPIRELFAN
- EPIZOLONE-DEPOT
- HYDROCORTISONE

## CNS

- EIPICOPENTIN
- OLAZINE
- LEVEPSY
- TRITICO
- RISDAL
- EPISTIGMIN
- FLUTIN
- EPIVAL
- NORMOLEPSY

## BRONCHODILATORS

- BRONCHOLIN S
- EIPICOPHYLLINE
- EIPICOPHYLLINE PHENOBARBITONE

## COUGH & COLD PREPARATIONS

- Flubronk
- GUFIDREXN
- SELGON
- BRONCHOPHANE
- NEO-BRONCHOPHANE
- CETAL COLD & FLU
- CETAL SINUS
- CONTA FLU

## ANTIHISTAMINICS & HISTAMINE ANALOGUE

- BREVY
- HISTOTIC
- EPIRIZINE
- ALLERGEX
- ALLERGEX CAFFEINE
- FEXOSTADINE

## ANAESTHETICS

- THIOPENTAL
- KETAM

## SYSTEMIC BLOOD COAGULANTS

- EPIKAVIT
- PROTAM

## ANTI-GOUT

- NO-URIC

## DERMATOLOGICALS

- EPICOMB
- BETADERM
- CAMISAN
- NYSTAFORM
- ALLERGEX
- MINOX

## UROLOGICALS

- SILDEN
- EPIMAG
- OXYBIN
- DOSIN

## MINERALS & ELECTROLYTES

- POTASSIUM CHLORIDE
- CALCIUM CHLORIDE
- MAGNESIUM SULPHATE





# EIPICO... ..rivalry forces

## Global Presence

over the years EIPICO implemented revolutionary penetrative strategies in different Regions as (MENA, UK, EU, Africa, Far East and Latin America) and Expanded it's presence in 74 countries around the Globe

## Business Model Versatility

EIPICO applies its expansion plans with different business models as Regional presentation, out-licensing through national Agency presentation and Contract Manufacturing for meeting different Global Partners needs in different territories.

## Flexibility

Flexibility and personalization of services and products offered to our distributors is one of the main competitive forces of EIPICO, this translates to offering Customized Packaging Specs, Languages and implementation of medication required specs of each destination we export to.

## Diversified portfolio


EIPICO portfolio mix is not limited to the 300 registered Pharmaceutical product covering 24 therapeutic class but also extends to hosting the know how of under-license brands of Allied license holders .

## Pricing competitiveness

EIPICO successful business strategies guarantees the Maximum profit for it's partners with Competitive pricing schemes to different markets.

## Distinctives

EIPICO is known for benchmarking International Regulatory Support to stakeholders by providing e-CTD Dossiers and familiarity with international health authorities regulations and inquiries.



## Quality Control

### **We foster a quality control culture based on:**

Highly qualified/proactive and well trained personnel,  
an environment of continuous improvement and  
A robust ISO 17025 accredited laboratory that provides  
the most accurate results through utilization  
of the up to date sensitive and precise instruments,  
validated test methods and procedures and implementation  
of laboratory information management system LIMS  
that automate all laboratory instruments, processes  
and ensures accuracy, availability, tractability, security  
and integrity of data.

## Quality Assurance

Every member in our team has a significant role to play  
in order to achieve our mission successfully by bringing  
high quality pharmaceutical products to the Egyptian  
and International markets.

We are certain that our values are embedded in our culture  
and our decision making helps us to meet the expectations  
of the society. We encourage associates to achievement  
through organized collaboration. Consequently, our quality  
members are provided with the right decision making  
authority giving a guarantee for short decision routes.

## Pharmacovigilance

Pharmacovigilance is defined by the World Health Organization (WHO) as “the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem”. Both clinical trials safety and post-marketing pharmacovigilance are critical throughout the product lifecycle. Although everyone's top concern is safety, adverse effects from medications are nevertheless possible. Thankfully, there are numerous measures in place to aid in safeguarding persons who take medications. Voluntary reporting of side effects for our medicinal products assists us in ensuring the safety of our products and patients. Your information will enable EIPiCo to fulfill its reporting responsibilities to health authorities, which requires continuous monitoring of the products' effectiveness and safety under real-life conditions post release, even in cases where a relationship between the product and the effect is not established.

### **Report... Your Report Counts.**

Any suspected adverse reactions to our medicinal products can be reported to us by email or by calling our free helpline.

**E-mail** : [Pharmacovigilance@eipico.net](mailto:Pharmacovigilance@eipico.net)  
**Mobile** : (24 hours) : (+2) 01005870200

## Regulatory Affairs

Pharmaceutical field is one of the most regulated industries and consequently Regulatory Affairs Team is the key player to ensure that our medicinal products comply with all regulations and laws of either Egyptian Drug Authority or International Regulatory Agencies.

We assure that all activities involving pharmaceutical products from licensing, registration and re-registration, variations, pricing and labelling are conducted in compliance with all applicable rules

We insure tracking of the ever-changing legislation in all regions through maintaining a vital communication links and giving a good advice on legal and scientific base, avoiding any regulatory constraints and finally, giving strategic and technical advice to maintain product registrations actively for one of the biggest portfolios in Pharmaceutical Companies.

## Research & Development

**R&D** department supports the social responsibility of the company to provide safe, effective, sustainable & environment-friendly products, that's why we invest annually to upgrade our state-of-the-art labs.

Our R&D team serves the company vision to cover & maintain the wide portfolio of the products in the local & global markets.

Considering EIPICO is the biggest medicine exporter in Egypt, our development process is complying with the recent quality guidelines like quality by design, process optimization & lifecycle management.



## Alliances

**EIPICO** has production and under license agreements with many multinational companies.

They all trust our quality standards, experience and capabilities.



# Data Matrix

“ **EIPICO implements a Track and Trace Program based on GS1 Data Matrix, the most widely used identification system worldwide, to ensure patient safety and enhance supply chain efficiency.** “



The problem of counterfeit drugs is not a new one, but it is a growing issue and one that cannot be ignored. It has become an increasing global threat over the last few decades.

EIPICO, as a leading pharmaceutical manufacturer, was of the first to use GS1 DataMatrix which is a system in which the supplier can mark items in the expectation that all trading partners will be able to read and correctly interpret the data encoded.

This DataMatrix is a (2D or two-dimensional) barcode which may be printed as a square or rectangular symbol made up of individual dots or squares.

GS1 DataMatrix encodes information such as, but not limited to: Global Trade Item Number (GTIN), a globally unique identification number for medical products, Expiration Date, Batch Number and Serial Number.

GS1 defines trade items as products or services that are priced, ordered or invoiced at any point in the supply chain.

GTIN once assigned to a trade item, it provides a common language for all of its entities and trading partners worldwide to uniquely identify the item and easily communicate information about the item.

The company's central Track and Trace system has been linked to the export warehouse system in a fully automatic manner.

The technical requirements for Track and Trace system have been completed and operated for the countries of Bahrain, the United Arab Emirates and the Sultanate of Oman in accordance with the laws and regulations of these countries to register the company and its products.

The fourth level of Track and Trace system has been applied, in which batches are automatically sent to European HUB - Saudi Arabia and the Gulf area,

## Track, Trace & Aggregation

EIPICO is one of the leading companies that have implemented the highest levels of drug tracking system. Level 4 Track, Trace & Aggregation, in compliance with the latest global and local requirements, linking with the networks of European countries Tracelink & EMVO, as well as with the networks of the Arab Gulf states and the Saudi Food and Drug Authority, which helps preventing product fraud, and facilitates the tracking of preparations in the markets. In parallel with passing the tests of the Egyptian Ministry of Health to verify the efficiency of the management of this system and its compatibility with the Ministry's systems.

Recently, Track & trace system is completed on semi-automatic production machines and Antares Vision machines & has been linked to the export warehouse system in a fully automatic manner.

# EIPICO pharma 4.0 project for digital transformation

- EIPICO aims with this project to apply the technologies of the Fourth Industrial Revolution and the required phases for a comprehensive digital transformation of the elements of production lines, supply chains and warehouses through the use of the global technical expertise.
- The **EIPICO Pharma 4.0** project reflects EIPICO's pioneering role in developing the pharmaceutical industry in Egypt with the state's vision in localization the pharmaceutical industry in Egypt through the application of the most advanced worldwide technological methods, **EIPICO Pharma 4.0** is an open platform, that maintains one-step connectivity between all nodes to the core, while allowing all nodes a robust access to data / information generated by other nodes. Also allows for a sustainable dependency between nodes, and a structured storage of data (Namespace) that provides huge opportunities for scaling analytics on the long-term.
- EIPICO is the first Egyptian pharmaceutical company to penetrate this field in MENA Region through this promising project **EIPICO Pharma 4.0** Industry for the digital transformation of about 43 production lines in the company, using the latest technologies of artificial intelligence, robots and " Industrial Internet Of Things I IOT " technology to digitize the all production process,

- taking measurements and recording readings automatically and instantaneously with automatic control of the machines, an integrated analysis of all the elements of the production process, and even forecasting malfunctions in production lines or facilities, alerting to take the necessary actions to avoid their occurrence in advance, prevents the occurrence of any human error at any step of production, reduces costs and maximizes the optimal use of raw materials, equipment, production lines, and energy used, and linking it with the company's ERP system to achieve homogeneity between all departments, to maximize the benefit of the project, improve and develop the decision-making mechanism, It's worthy to be mentioned that , **EIPICO pharma 4.0** project Achieving many strategic benefits such as the principles of governance, with the highest levels of transparency in line with the sustainable development goals.





# EIACO

# EIPICO Plastic Factory


EIPICO decided to establish affiliated factories, in the field of industries feeding the pharmaceutical industries, to ensure the constant, sufficient availability of primary packaging materials, and to avoid the problems of import (shipping and foreign currencies)

In 2005, Egyptian International Ampoules Company – EIACO was established, as an Egyptian investment company for manufacturing medical ampoules, over the area of 25,000 M<sup>2</sup> in 10th of Ramadan city. EIPICO is the main investor.

In 2007 EIACO started production with 80 Million Ampoules and currently produce



333 Million unit / year :  
180 Million Ampoules  
120 Million Vials of type 1 Vial  
33 Million aluminum tubes



In 2018 EIACO is accredited the quality certificate ISO 9001 /2015. With 450 employees, EIACO is currently the largest manufacturer of primary packing materials in Egypt, managing to completely secure the needs of EIPICO from Ampoules, Vials and Aluminum Tubes, which reflects the great success in achieving the strategic object of its establishment.

The main goal of establishing the factory was far beyond achieving any financial gain, but only to maintain the high quality level of EIPICO's Eye Drops assuring the sterility of the medicament all through the production process up to the end user.

This target was not achievable regarding the low quality of the locally-produced eye drops bottles.

Since the beginning and up till now, the factory covered all EIPICO's needs of Eye Drops Dropper Bottles, Sizes: 5, 10, and 15 ml, with a quality level that matches the highest international standards, and was capable of developing its productivity to fulfill future needs.



## Factory of Batterjee Company for Pharmaceutical Products and Medical Appliances (Batterjee Pharma)

After achieving remarkable success both in local and foreign markets, constructing a brilliant reputation for the quality of its products, as well as its trade name, **EIPICO** has decided to transfer its technology via collaboration with foreign parties through establishing joint venture pharmaceutical companies.



**Batterjee Pharma** is **EIPICO**'s first investment abroad in manufacturing pharmaceutical products.

**Batterjee Pharma** started with a capital of 60 Million Saudi Riyals, currently raised to **77 Million Saudi Riyals**. **EIPICO** owns a **30%** stake.

**Batterjee Pharma** was established in 2008, and started production in 2009, located in **Saudi Arabia** - Jeddah - Industrial Zone Phase IV, on **12,000 m<sup>2</sup>**.

**Batterjee Pharma** has 150 employees.

**Batterjee Pharma** is licensed to produce all pharmaceutical dosage forms, currently manufacturing **30 products**.



**Batterjee Pharma** exports to **Bahrain, UAE, and Yemen**.

## Acquisition of a 10% stake of MUP

@ 2020 The board of directors of the Egyptian International Pharmaceutical Industries (**EIPICO**) has approved the acquisition of a 10% stake of the Medical Union Pharmaceuticals (**MUP**), equivalent to 4.89 m shares.



## Contact us

### FACTORIES & MAIN OFFICE

Tenth of Ramadan

Address: EIPICO, Tenth of Ramadan City - 1st Industrial

Zone B1, Egypt.

Telephone: +20554499199. Fax: +20554499306.

E-mail: eipico@eipico.com.eg

- Tenth of Ramadan Branch:  
Tenth of Ramadan City - Industrial Area B 1 (Factory 1 and Factory 2)  
0554499199 & Fax: 0554499306  
E-mail: tenth@eipico.net

### OUR BRANCHES

- Cairo & Giza Branches  
Address: 3, El Moez Ledin Allah St. from Asmaa Fahmy St., Ard El Golf, Nasr City,  
Cairo.  
Tel: 0224143660 & 0224143550  
E-mail: cairo@eipico.net  
E-mail: giza@eipico.net
- Alexandria Branch.  
Address: New Mansheya - Muharram Bek - Bridges  
Highway - The Land of Alexandria Refrigeration Company.  
Tel: 03 3600612 - 03 3600615 - 03 3600616 - 03 3600618  
E-mail: alex@eipico.net

- Mansoura Branch  
Address: 13, El-Emiam El Ghazali St., Toreil, El Mansoura  
Second, Dakahlia.  
Tel: 050 2328811  
E-mail: Mansora@eipico.net
- Banha & Tanta Branches  
Address: 63, Banha El Zagazig Rd., Qism Banha, Qalyubia.  
Tel: 013 3229020 - 01220700406 - 01220700408  
E-mail: Banha@eipico.net  
Tanta@eipico.net
- Menia Branch  
Address: Stores and Warehouses "Development  
and Agricultural Credit Bank" - First railway Telah - Minya.  
Tel: 086 2351480 - 086 2351474  
E-mail: Menia@eipico.net
- Sohag Branch  
Address: Rawafie Al-Kousair, Sohag.  
Tel: 093 2334652  
E-mail: sohag@eipico.net



**CONTACT**

**US**



Visit the Website



EGYPTIAN INT. PHARMACEUTICAL INDUSTRIES CO.  
10th of Ramadan City – Industrial Area B1 – Egypt  
Tel.: 0554/499199 - Fax: 0554/499306

